Merck
Merck KGaA’s sales climb but key drugs fall
May 19, 2015Sales and Marketing Erbitux, Merck, Merck KGaA, Q1, Rebif
Merck KGaA encountered an uneven start to 2015, with robust sales in the first quarter offset by declines in key …
Merck KGaA reveals ASCO plans
May 15, 2015Sales and Marketing ASCO, Merck, Merck KGaA, Merck Serono, avelumab
Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, and like other firms it …
Merck to test Keytruda combinations
May 8, 2015Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
New app can aid tropical disease treatment
May 8, 2015Medical Communications, Sales and Marketing Merck, app, smartphone, tropical diseases
A new smartphone app is able to automatically detect parasites in the blood and may mark a fundamental shift in …
Merck sales fall in Q1 despite new product lifts
April 29, 2015Sales and Marketing Merck, Q1, Remicade
Merck’s sales were down in the first quarter of 2015 thanks to its consumer care divestment and increasing competition for …
GSK shingles vaccine performs
April 29, 2015Research and Development, Sales and Marketing GSK, GlaxoSmithKline, HZ/su, Merck, zostovax
GlaxoSmithKline’s HZ/su vaccine candidate for the prevention of shingles has demonstrated promising benefits across all age groups in a late-stage …
Conference round-up: companies go big on hepatitis C at EASL
April 29, 2015Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza
Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
Cristal Therapeutics hires chief business officer from Merck
April 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cristal Therapeutics, Jeroen Tonnaer, Merck
Jeroen Tonnaer has been named as the new chief business officer responsible for Cristal Therapeutics’ business development, partnering and licensing …
Merck Serono gains head of global clinical development
April 17, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alise Reicin, Merck, Merck Serono
Merck Serono, the biopharma business of Merck, has appointed Dr Alise Reicin as senior vice president and head of its …
Merck hires life sciences business head
April 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, Merck Millipore, Sigma-Aldrich, udit batra
Merck has confirmed that the current chief executive and president of Merck Millipore Dr Udit Batra has been appointed to lead …
Merck and Pfizer to co-promote cancer drug
April 9, 2015Research and Development, Sales and Marketing Cancer, Merck, Merck KGaA, NSCLC, Pfizer, Xalkori, non-small cell lung cancer, oncology
Merck KgaA and Pfizer have agreed to co-promote the latter’s lung cancer treatment Xalkori, and form a new alliance that …
Merck Ebola vaccine safe and effective in latest trials
April 2, 2015Research and Development, Sales and Marketing Ebola, Merck, National Institutes of Health, VSV-ZEBOV, Vaccine, Walter Reed Army Institute of Research, newlink
Merck and NewLink’s experimental Ebola vaccine has been found to be safe and effective in a new trial in the …
Merck lines up early-stage Keytruda combo trial
April 1, 2015Research and Development, Sales and Marketing Cancer, Merck, entinostat, keytruda, pd1, pembrolizumab, syndax
Merck is planning for Keytruda’s future by launching early-stage trials of the drug in combination with an investigational treatment from …
Merck Serono in $826m immuno-oncology deal
March 31, 2015Research and Development, Sales and Marketing Intrexon, Merck, Merck Serono, T cell, biopharma, cart, immuno-oncology, t-cell
Merck Serono has announced a significant deal with Intrexon to develop and bring new cancer treatments to market. The German …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
